Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Peripheral T-cell lymphomas (PTCL) have historically poor prognoses.
• Stem cell transplant (SCT) is a critical therapeutic option for PTCL.
• Relapse after SCT is a significant challenge in PTCL management.

Purpose of the Study:

• To review the current utilization and efficacy of maintenance therapy post-SCT for PTCL.
• To explore emerging agents and future directions for PTCL maintenance strategies.

Main Methods:

• Review of ongoing and completed clinical trials on post-SCT maintenance therapy in PTCL.
• Analysis of data from studies investigating specific agents like romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab.

Main Results:

• Maintenance therapy is increasingly employed to mitigate post-SCT relapse in PTCL.
• Clinical trials indicate that agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab demonstrate efficacy in reducing relapse rates.
• Emerging agents show potential for future PTCL maintenance strategies.

Conclusions:

• Post-SCT maintenance therapy represents a promising strategy to sustain remission in PTCL patients.
• Current evidence suggests maintenance therapy can effectively decrease the incidence of relapse after SCT.
• Further trials are ongoing to solidify the role of maintenance therapy in optimizing PTCL outcomes.